Vasoactive intestinal peptide (VIP) is a 28-amino acid polypeptide first isolated from swine duodenum. VIP is a neurotransmitter that is extensively distributed in tissues. According to published reports, VPAC1 and VP...Vasoactive intestinal peptide (VIP) is a 28-amino acid polypeptide first isolated from swine duodenum. VIP is a neurotransmitter that is extensively distributed in tissues. According to published reports, VPAC1 and VPAC2 act as VIP receptors and are widely present in the central nervous system and peripheral tissues. VIP exerts diverse actions on the cardiovascular system, pancreas, digestive tract, respiratory system, and urological system. Recent reports indicated that VIP has immunological and neuroprotective effects and also affects cell growth. While primary investigations for developing therapeutic applications for various pathological conditions and diseases are underway, the structure and function of VIP should be analyzed in more detail.展开更多
目的:观察血管活性肠肽(vasoactive intestinal peptide,VIP)对便秘大鼠肠道水液代谢、环磷酸腺苷-蛋白激酶A信号通路(cyclic AMP protein kinase A signaling pathway,c AMP-PKA)和水通道蛋白3(water channel protein 3,AQP3)的影响,探...目的:观察血管活性肠肽(vasoactive intestinal peptide,VIP)对便秘大鼠肠道水液代谢、环磷酸腺苷-蛋白激酶A信号通路(cyclic AMP protein kinase A signaling pathway,c AMP-PKA)和水通道蛋白3(water channel protein 3,AQP3)的影响,探讨VIP治疗便秘的作用及机制。方法:45只健康成年Sprague-Dawley大鼠随机分为空白对照组、模型组、模型+VIP组。给药4周后,墨汁灌胃法检测大鼠首粒黑便排出时间;根据大鼠粪便干湿重计算粪便含水率;HE染色观察各组大鼠结肠组织形态学变化;Western印迹检测各组大鼠结肠组织中VIP和AQP3蛋白表达水平;定量即时聚合酶链锁反应(quantitative real time polymerase chain reaction,q PCR)检测各组大鼠结肠组织中c AMP,PKA和AQP3 m RNA的表达水平。结果:与空白对照组比较,模型组大鼠首粒黑便出现时间延长,粪便含水率明显减少(均P<0.01);结肠黏膜上皮部分破坏,杯状细胞体积减小,数量明显减少;结肠组织中VIP和AQP3蛋白含量明显减少,AQP3,c AMP和PKA m RNA相对表达水平均有所降低(均P<0.05)。与模型组比较,模型+VIP组大鼠首粒黑便出现时间缩短,粪便含水率明显增加(均P<0.05);结肠黏膜上皮完整性明显改善,杯状细胞体积增大,数量增多;结肠组织中VIP和AQP3蛋白含量增多,CAMP,PKA和AQP3 m RNA相对表达水平升高(均P<0.05)。结论:VIP静脉注射能够调节肠道水液代谢,改善大鼠便秘症状,其机制可能与调节VIP-c AMP-PKA-AQP3信号通路有关。展开更多
目的：观测消风散加味对慢性持续期支气管哮喘呼出气一氧化氮浓度（fractional concentration of exhaled nitricoxide,FeNO）,血浆P物质（substance P,SP）和血管活性肠肽（vasoactive intestinal peptide,VIP）含量的影响,探讨其治疗...目的：观测消风散加味对慢性持续期支气管哮喘呼出气一氧化氮浓度（fractional concentration of exhaled nitricoxide,FeNO）,血浆P物质（substance P,SP）和血管活性肠肽（vasoactive intestinal peptide,VIP）含量的影响,探讨其治疗支气管哮喘的可能作用机制。方法：选取符合纳入标准的支气管哮喘患者80例,随机分为对照组和治疗组。对照组给予布地奈德福莫特罗粉吸入剂（160μg/4.5μg）,早晚各2吸。治疗组在对照组治疗的基础之上给予消风散加味,每日1剂。两组疗程均为1个月。观察治疗前后两组患者肺功能相关指标第1秒末用力呼气量（forced expiratory volume in first second,FEV1）,第1秒末用力呼气量占用力肺活量百分比（percentage of forced expiratory volume in first second and forced vital capacity,FEV1/FVC）,1 s用力呼气量占预计值百分比（percentage of forced expiratory volume in first second and its predicted value,FEV1%）,呼气流量峰值变异率（variety ratio of peak expiratory flow,PEF）,FeNO,血浆SP,VIP水平变化,并记录两组患者不良反应。结果：治疗后两组患者肺功能指标FEV1,FEV1/FVC,FEV1%比较,治疗组均高于对照组（P〈0.05）;PEF变异率比较,治疗组低于对照组（P〈0.05）;治疗后治疗组患者FeNO,血浆SP水平均低于对照组（P〈0.05）,治疗组VIP水平高于对照组（P〈0.05）;两组患者不良反应总发生率比较,治疗组低于对照组（P〈0.05）。结论：消风散加味联合布地奈德福莫特罗粉吸入剂治疗支气管哮喘与单用布地奈德福莫特罗粉吸入剂治疗相比较,可更有效改善支气管哮喘患者的肺功能,调节神经源性气道炎症水平,同时降低不良反应发生率,值得推广应用。展开更多
文摘Vasoactive intestinal peptide (VIP) is a 28-amino acid polypeptide first isolated from swine duodenum. VIP is a neurotransmitter that is extensively distributed in tissues. According to published reports, VPAC1 and VPAC2 act as VIP receptors and are widely present in the central nervous system and peripheral tissues. VIP exerts diverse actions on the cardiovascular system, pancreas, digestive tract, respiratory system, and urological system. Recent reports indicated that VIP has immunological and neuroprotective effects and also affects cell growth. While primary investigations for developing therapeutic applications for various pathological conditions and diseases are underway, the structure and function of VIP should be analyzed in more detail.
文摘目的:观察血管活性肠肽(vasoactive intestinal peptide,VIP)对便秘大鼠肠道水液代谢、环磷酸腺苷-蛋白激酶A信号通路(cyclic AMP protein kinase A signaling pathway,c AMP-PKA)和水通道蛋白3(water channel protein 3,AQP3)的影响,探讨VIP治疗便秘的作用及机制。方法:45只健康成年Sprague-Dawley大鼠随机分为空白对照组、模型组、模型+VIP组。给药4周后,墨汁灌胃法检测大鼠首粒黑便排出时间;根据大鼠粪便干湿重计算粪便含水率;HE染色观察各组大鼠结肠组织形态学变化;Western印迹检测各组大鼠结肠组织中VIP和AQP3蛋白表达水平;定量即时聚合酶链锁反应(quantitative real time polymerase chain reaction,q PCR)检测各组大鼠结肠组织中c AMP,PKA和AQP3 m RNA的表达水平。结果:与空白对照组比较,模型组大鼠首粒黑便出现时间延长,粪便含水率明显减少(均P<0.01);结肠黏膜上皮部分破坏,杯状细胞体积减小,数量明显减少;结肠组织中VIP和AQP3蛋白含量明显减少,AQP3,c AMP和PKA m RNA相对表达水平均有所降低(均P<0.05)。与模型组比较,模型+VIP组大鼠首粒黑便出现时间缩短,粪便含水率明显增加(均P<0.05);结肠黏膜上皮完整性明显改善,杯状细胞体积增大,数量增多;结肠组织中VIP和AQP3蛋白含量增多,CAMP,PKA和AQP3 m RNA相对表达水平升高(均P<0.05)。结论:VIP静脉注射能够调节肠道水液代谢,改善大鼠便秘症状,其机制可能与调节VIP-c AMP-PKA-AQP3信号通路有关。
文摘目的：观测消风散加味对慢性持续期支气管哮喘呼出气一氧化氮浓度（fractional concentration of exhaled nitricoxide,FeNO）,血浆P物质（substance P,SP）和血管活性肠肽（vasoactive intestinal peptide,VIP）含量的影响,探讨其治疗支气管哮喘的可能作用机制。方法：选取符合纳入标准的支气管哮喘患者80例,随机分为对照组和治疗组。对照组给予布地奈德福莫特罗粉吸入剂（160μg/4.5μg）,早晚各2吸。治疗组在对照组治疗的基础之上给予消风散加味,每日1剂。两组疗程均为1个月。观察治疗前后两组患者肺功能相关指标第1秒末用力呼气量（forced expiratory volume in first second,FEV1）,第1秒末用力呼气量占用力肺活量百分比（percentage of forced expiratory volume in first second and forced vital capacity,FEV1/FVC）,1 s用力呼气量占预计值百分比（percentage of forced expiratory volume in first second and its predicted value,FEV1%）,呼气流量峰值变异率（variety ratio of peak expiratory flow,PEF）,FeNO,血浆SP,VIP水平变化,并记录两组患者不良反应。结果：治疗后两组患者肺功能指标FEV1,FEV1/FVC,FEV1%比较,治疗组均高于对照组（P〈0.05）;PEF变异率比较,治疗组低于对照组（P〈0.05）;治疗后治疗组患者FeNO,血浆SP水平均低于对照组（P〈0.05）,治疗组VIP水平高于对照组（P〈0.05）;两组患者不良反应总发生率比较,治疗组低于对照组（P〈0.05）。结论：消风散加味联合布地奈德福莫特罗粉吸入剂治疗支气管哮喘与单用布地奈德福莫特罗粉吸入剂治疗相比较,可更有效改善支气管哮喘患者的肺功能,调节神经源性气道炎症水平,同时降低不良反应发生率,值得推广应用。
